Lysyl Oxidases as Targets for Cancer Therapy and Diagnostic Imaging.

The understanding of the contribution of the tumour microenvironment to cancer progression and metastasis, in particular the interplay between tumour cells, fibroblasts and the extracellular matrix has grown tremendously over the last years. Lysyl oxidases are increasingly recognised as key players in this context, in addition to their function as drivers of fibrotic diseases. These insights have considerably stimulated drug discovery efforts towards lysyl oxidases as targets over the last decade. This review article summarises the biochemical and structural properties of theses enzymes. Their involvement in tumour progression and metastasis is highlighted from a biochemical point of view, taking into consideration both the extracellular and intracellular action of lysyl oxidases. More recently reported inhibitor compounds are discussed with an emphasis on their discovery, structure-activity relationships and the results of their biological characterisation. Molecular probes developed for imaging of lysyl oxidase activity are reviewed from the perspective of their detection principles, performance and biomedical applications.

Vascular Ehlers-Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches.

Vascular Ehlers-Danlos syndrome (vEDS) is a rare autosomal dominant genetic disorder. It is the most fatal among all types of EDS. In addition to typical EDS characteristics, vEDS patients are at risk of blood vessel rupture due to possession of pathogenic variants of the COL3A1 gene, which encodes type III collagen. Type III collagen is a major component of humans' vascular walls. The management of this disease is possible; however, there is no cure as of present. Recently, discoveries with potential impact on the management of vEDS have been elucidated. Mice with vEDS traits treated with a beta-blocker celiprolol showed significant improvements in their thoracic aorta biomechanical strength. Moreover, it has been demonstrated that the specifically designed small interference RNAs (siRNA) can effectively silence the pathogenic variant allele. To enhance the normal allele expression, an intracellularly expressed lysyl oxidase is shown to regulate the transcription rate of the COL3A1 promoter. Similarly, an embryonic homeobox transcription factor Nanog upregulates the wild-type COL3A1 expression through activation of the transforming growth factor-beta pathway, which increases type III collagen synthesis. Despite numerous advancements, more studies are to be performed to incorporate these discoveries into clinical settings, and eventually, more personalized treatments can be created.

Inhibition of angiogenesis in endothelial cells by Human Lysyl oxidase propeptide.

Angiogenesis is a critical process involved in normal physiology. Pathological angiogenesis is observed in vascular diseases and neoplasia. The propeptide domain of LOX (LOX-PP) has been shown to inhibit tumorigenesis in various cancers. In this study, we explored the role of both overexpressed and recombinant LOX-PP in naïve human umbilical vein endothelial cell with the addition of vascular endothelial growth factor (VEGF). Primarily, we observed a significant reduction in the angiogenesis signaling pathways upon LOX-PP overexpression by proteomic analysis. Further functional analysis showed that the VEGF induced cell proliferation, migration, adhesion and tube formation was inhibited by LOX-PP. Moreover, LOX-PP arrested cells at S-phase, reduced F-actin levels and decreased phosphorylation of focal adhesion kinase (FAK) and extracellular signal regulated kinase (ERK). The anti-angiogenic effect of LOX-PP was further confirmed by the reduction in the vascular network formation in chick chorioallantoic membrane (CAM). These results indicate that inhibition of angiogenesis events is not only achieved by overexpressing LOX-PP but also by addition of rLOX-PP. Taken together our findings discovered the anti-angiogenic role of LOX-PP in endothelial cells which suggests that harnessing this potential can be a promising strategy to inhibit angiogenesis.

Función e importancia clínica de la enzima lisil-oxidasa / Role and clinical significance of the lysyl oxidase enzyme / Funções e importância clínicas da enzima lisil-oxidase

La lisil-oxidasa (LOX) es una quinoenzima que contiene cobre y lisil-tirosilquinona como cofactor. Esta amino-oxidasa actúa en la catálisis de la desaminación oxidativa de residuos de lisina en los precursores del colágeno y de elastina. Anteriormente se ha informado sobre su biosíntesis, sus propiedades catalíticas y mecanismo de reacción, cofactores e inhibidores, así como la expresión y respuesta a diversos efectores celulares. En este trabajo se analizan las funciones e implicancias clínicas de LOX ya que sus niveles aumentan en muchas enfermedades fibróticas y en algunos tumores, con lo que promueven metástasis, mientras que la expresión de la enzima está disminuida en enfermedades que involucran un deterioro en el metabolismo del cobre. LOX tiene funciones paradójicas en cáncer puesto que actúa tanto en la supresión como en la promoción tumoral. Se plantea su rol en la aterogénesis y la disfunción endotelial, en trastornos oculares, fibrosis, enfermedades iatrogénicas, regeneración ósea y aumento del riesgo de enfermedades cardiovasculares, entre otras. Se encaran los últimos avances referidos a la acción proangiogénica del cobre y las funciones de la proteína precursora de LOX, cuyos niveles de expresión están asociados con diversos tipos de cáncer.

Lysyl oxidase (LOX) is a copper-containing quinoenzyme, having lysyl-tyrosyl-quinone as cofactor. This amino oxidase catalyzes the oxidative deamination of lysine residues in collagen and elastin precursors. Its biosynthesis, catalytic properties and reaction mechanism, cofactors and inhibitors as well as expression and response to various cellular effectors have previously been reported. In the present paper, functions and clinical implications of LOX are analyzed, since LOX levels are increased in many fibrotic diseases, and in some tumors promoting metastasis, whereas the expression of the enzyme is decreased in diseases involving deterioration in copper metabolism. LOX shows paradoxical roles in cancer both suppressing and promoting tumors. The role of LOX in atherogenesis and endothelial dysfunction, eye disorders, fibrosis, iatrogenic diseases, bone regeneration, and increased risk of cardiovascular disease, among others, are addressed. Recent developments related to the proangiogenic action of copper and functions of LOX precursor protein, whose expression levels are associated with various cancers, are discussed.

A lisil oxidase (LOX) é uma quinoenzima contendo cobre e lisil-tirosil-quinona como cofator. Esta amino oxidase atua na catálise da desaminação oxidativa de resíduos de lisina de precursores de colágeno e elastina. Anteriormente foi informado sobre sua biossíntese, suas propriedades catalíticas e mecanismo de reação, cofatores e inibidores, bem como a expressão e resposta a vários efetores celulares. Neste trabalho as funções e implicações clínicas de LOX são analisadas visto que seus níveis aumentam em muitas doenças fibróticas e em alguns tumores promovendo metástases, enquanto que a expressão da enzima está reduzida em doenças que envolvem deterioração no metabolismo do cobre. LOX tem funções paradoxais em câncer, uma vez que atua tanto na supressão quanto na promoção tumoral. Discute-se ser papel na aterogênese e disfunção endotelial, distúrbios oculares, fibrose, doenças iatrogênicas, regeneração óssea e aumento do risco de doença cardiovascular, dentre outras. São encarados os últimos avanços associados com a ação pró-angiogênica do cobre e as funções da proteína precursora de LOX, cujos níveis de expressão estão associadas com vários tipos de câncer.

Overexpression of lysyl oxidase to increase matrix crosslinking and improve tissue strength in dermal wound healing.

In this study, we aimed to increase crosslinking in collagen and elastin in the extracellular matrix through overexpression of lysyl oxidase (LO) in order to improve mechanical strength in dermal wounds during healing. We had used a gene activated matrix (GAM) approach to locally deliver plasmid DNA (pDNA) complexed with polyethylenimine (PEI) in collagen gels at the wound site for localized and sustained transfection of cells involved in the healing process. We first demonstrated in vitro that PEI-pDNA complexes in collagen gels could be taken up and expressed by cultured fibroblasts for at least 20 days. In vitro studies showed that fibroblast-seeded GAMs with the LO transgene exhibited over a 3-fold increase in mechanical strength as compared with a green fluorescent protein (GFP)-transgene control. Addition of an inhibitor of LO abolished this increase. We applied this system in a rat dermal wound healing model and showed that treatment with LO-producing GAMs led to significantly enhanced mechanical strength of the wound site.

Targeted gene therapy toward astrocytoma using a Cre/loxP-based adenovirus system.

The aim of this study was to establish a novel adenovirus-based gene therapy system targeting astrocytoma. For this purpose, the Cre recombinase (Cre)/loxP system together with the astrocytoma-specific promoter for GFAP were used. We constructed an adenovirus (Ad) vector that expressed Cre under the control of the GFAP promoter (AxGFAPNCre), as well as another Ad vector containing a switching unit. The latter vector contained a stuffer sequence encoding GFP (AxCALGLTK) with a functional polyadenylation signal between two loxP sites, followed by the herpes simplex virus thymidine kinase (HSV-TK) gene under the control of the CAG promoter. In this system, gene expression of either the stuffer sequence (GFP) or the downstream gene (HSV-TK) was switched on by co-expression of Cre recombinase. Western blot analysis demonstrated specific expression of high levels of TK protein in C6 glioma cells after co-infection of AxGFAPNCre and AxCALGLTK. In vivo, AxGFAPNCre/AxCALGLTK injection into C6 gliomas in the subcutaneous tissue of nude mice followed by intraperitoneal ganciclovir (GCV) treatment significantly suppressed tumor growth compared with control mice. Co-infection of AxGFAPNCre and AxCALNLLacZ resulted in LacZ expression in C6 glioma cells and some reactive astrocytes, whereas GFP was expressed in other cell types surrounding the injected site. Furthermore, a combination of AxGFAPNCre/AxCALGLTK and intraperitoneal GCV injection significantly regressed intracranial C6 gliomas in the rat striatum and prolonged the survival time compared with control rats. The present results indicate that this cell-type-specific gene therapy using a Cre/loxP adenovirus system is both operational and effective, at least against astrocytoma.

A new antitumor enzyme, L-lysine alpha-oxidase from Trichoderma viride. Purification and enzymological properties.

L-Lysine alpha-oxidase from Trichoderma viride Y244-2 has been purified to homogeneity. The enzyme shows absorption maxima at 277, 388, and 466 nm and a shoulder around 490 nm and contains 2 mol of FAD/mol of enzyme. The enzyme has a molecular weight of approximately 116,000 and consists of two subunits identical in molecular weight (about 56,000). In addition to L-lysine, L-ornithine, L-phenylalanine, L-tyrosine, L-arginine, and L-histidine are oxidized by the enzyme to a lesser extent. Several lysine analogs such as delta-hydroxylysine are oxidized efficiently. Balance studies showed that 1 mol of L-lysine is converted to an equimolar amount of alpha-keto-epsilon-aminocaproate, ammonia, and hydrogen peroxide with the consumption of 1 mol of oxygen. alpha-Keto-epsilon-aminocaproate spontaneously is dehydrated intramolecularly into delta 1-piperideine-2-carboxylate in the presence of catalase, and is oxidatively decarboxylated into delta-aminovalerate in the absence of catalase. The Michaelis constants are as follows: 0.04 mM for L-lysine, 0.44 mM for L-ornithine, 14 mM for L-phenylalanine, and 1.6 mM for oxygen with L-lysine.